Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects age ≥60 and ≤80 years at the time of signing the informed consent form.~2. Must show signs of frailty apart from a concomitant condition as assessed by the investigator with a frailty score of 1 to 4 using the Fried Phenotype Scale.~3. Must provide written informed consent.~4. Subjects are expected to live more than 12 months.~Exclusion Criteria:~1. Serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study~2. Advanced liver or renal failure, class III/IV congestive heart failure, myocardial infarction, unstable angina, cardiac revascularization, or severe obstructive ventilator defect.~3. Uncontrolled hypertension or hyperglycemia.~4. Have known allergies to biological drugs or antibiotics.~5. Expecting to receive organ transplantation.~6. Have a clinical history of malignancy or active autoimmune diseases.~7. Have a history of drug or alcohol abuse within the past 24 months.~8. Be serum-positive for HIV, hepatitis BsAg or viremic hepatitis C.~9. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.~10. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HUC-MSCs Group (Type: EXPERIMENTAL): Human umbilical cord mesenchymal stem cells (1\*10\^6/kg cells): delivered via peripheral intravenous infusion.
- Control Group (Type: PLACEBO_COMPARATOR): Placebo:normal saline delivered via peripheral intravenous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).